Education
About Us
Working with TipRanks
Follow Us
Hikal Limited (IN:HIKAL)
:HIKAL
HIKAL Stock Chart & Stats
₹227.05
-₹7.35(-1.92%)
At close: 4:00 PM EST
₹227.05
-₹7.35(-1.92%)
Day’s Range― - ―
52-Week Range₹166.00 - ₹456.60
Previous CloseN/A
Volume141.84K
Average Volume (3M)34.88K
Market Cap
₹21.42B
Enterprise Value₹27.42B
Total Cash (Recent Filing)₹340.00M
Total Debt (Recent Filing)₹7.20B
Price to Earnings (P/E)―
Beta1.10
Next Earnings
Jun 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.58%
Share Statistics
EPS (TTM)1.80
Shares Outstanding123,300,750
10 Day Avg. Volume44,586
30 Day Avg. Volume34,881
Financial Highlights & Ratios
PEG Ratio1.79
Price to Book (P/B)3.92
Price to Sales (P/S)2.66
P/FCF Ratio34.59
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)2
Revenue Forecast (FY)₹16.63B
Bulls Say, Bears Say
Bulls Say
High And Improving MarginsSustained high gross margin (55% TTM) and rising operating margins reflect durable process advantages and pricing power in specialty chemistry. This margin profile cushions input cost swings, funds R&D and capex, and supports healthier operating leverage over the medium term.
Strong Cash GenerationRobust cash conversion (OCF/net income 3.09) and material TTM free cash flow provide self‑funding capacity for capex, debt service and strategic investments. Reliable FCF reduces reliance on external financing and enhances resilience through industry cycles over multiple quarters.
Sticky B2B CDMO And R&D ModelA focused CDMO/CRAMS business serving pharma and crop protection with in‑house R&D creates recurring, contract‑based revenue and higher switching costs. Structural outsourcing trends in pharma/agro underpin long‑term demand and support repeatable, stickier customer relationships.
Bears Say
Inconsistent Revenue GrowthIntermittent top‑line performance limits visibility and undermines capacity planning and return on invested capital. Persistent revenue volatility can depress utilization, lengthen payback on incremental capex, and make multi‑period forecasting and client diversification harder.
Moderate LeverageA debt/equity of ~0.61 denotes moderate leverage that, while manageable, reduces financial flexibility. In the face of cyclical downturns or elevated capex needs, interest and principal commitments may constrain strategic moves or force higher external funding over the medium term.
Input‑cost ExposureMaterial exposure to raw material and energy price swings can compress margins and increase working capital volatility. For a chemical manufacturer, persistent commodity or energy inflation can erode free cash flow and require pricing renegotiations that take multiple quarters to implement.
Hikal Limited News
HIKAL FAQ
What was Hikal Limited’s price range in the past 12 months?
Hikal Limited lowest stock price was ₹166.00 and its highest was ₹456.60 in the past 12 months.
What is Hikal Limited’s market cap?
Hikal Limited’s market cap is ₹21.42B.
When is Hikal Limited’s upcoming earnings report date?
Hikal Limited’s upcoming earnings report date is Jun 18, 2026 which is in 90 days.
How were Hikal Limited’s earnings last quarter?
Hikal Limited released its earnings results on Feb 11, 2026. The company reported ₹1.8 earnings per share for the quarter, beating the consensus estimate of N/A by ₹1.8.
Is Hikal Limited overvalued?
According to Wall Street analysts Hikal Limited’s price is currently Overvalued.
Does Hikal Limited pay dividends?
Hikal Limited pays a Semiannually dividend of ₹0.8 which represents an annual dividend yield of 0.58%. See more information on Hikal Limited dividends here
What is Hikal Limited’s EPS estimate?
Hikal Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Hikal Limited have?
Hikal Limited has 123,300,750 shares outstanding.
What happened to Hikal Limited’s price movement after its last earnings report?
Hikal Limited reported an EPS of ₹1.8 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 0.977%.
Which hedge fund is a major shareholder of Hikal Limited?
Currently, no hedge funds are holding shares in IN:HIKAL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Hikal Limited
Hikal Limited, together with its subsidiaries, manufactures and sells various chemical intermediates, specialty chemicals, and active pharma ingredients to pharmaceutical, animal healthcare, biotech, crop protection, and specialty chemicals companies. It operates through two segments, Pharmaceuticals and Crop Protection. The Pharmaceuticals segment produces active pharmaceutical ingredient (APIs). The Crop Protection segment manufactures pesticides and herbicides. The company collaborates with other companies and offer solutions in contract research, custom synthesis, and custom manufacturing of intermediates and APIs. It also provides specialty biocides and antimicrobial actives, as well as additives for leather, paint coatings, paper, water treatment, personal care, building materials, and textile industries. The company was incorporated in 1988 and is headquartered in Navi Mumbai, India.
Technical Analysis
Indoco Remedies Limited
―
Morepen Laboratories Limited
―
RPG Life Sciences Limited
―
―
Unichem Laboratories Limited
―